APA (7th ed.) Citation

Bachert, C., Khan, A. H., Lee, S. E., Hopkins, C., Peters, A. T., Fokkens, W., . . . Rowe, P. J. (2024). Prevalence of type 2 inflammatory signatures and efficacy of dupilumab in patients with chronic rhinosinusitis with nasal polyps from two phase 3 clinical trials: SINUS‐24 and SINUS‐52. International Forum of Allergy & Rhinology, 14(3), 668. https://doi.org/10.1002/alr.23249

Chicago Style (17th ed.) Citation

Bachert, Claus, et al. "Prevalence of Type 2 Inflammatory Signatures and Efficacy of Dupilumab in Patients with Chronic Rhinosinusitis with Nasal Polyps from Two Phase 3 Clinical Trials: SINUS‐24 and SINUS‐52." International Forum of Allergy & Rhinology 14, no. 3 (2024): 668. https://doi.org/10.1002/alr.23249.

MLA (9th ed.) Citation

Bachert, Claus, et al. "Prevalence of Type 2 Inflammatory Signatures and Efficacy of Dupilumab in Patients with Chronic Rhinosinusitis with Nasal Polyps from Two Phase 3 Clinical Trials: SINUS‐24 and SINUS‐52." International Forum of Allergy & Rhinology, vol. 14, no. 3, 2024, p. 668, https://doi.org/10.1002/alr.23249.